Press Release: Aqualung Therapeutics : Aqualung Therapeutics Appoints Two New Board Directors; Will Attend ...

(PR-inside.com) TUCSON, AZ / ACCESSWIRE / June 8, 2022 / Aqualung Therapeutics, an early stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for serious unchecked inflammatory disorders, unanimously appointed two highly accomplished entrepreneurs and scientists to the recently formed Aqualung Therapeutics Board of Directors. Industry experts Donald Payan MD and Robert Schleimer PhD will officially begin their Board tenure in June. Dr. Payan is an experienced hands-on biotechnology physician-scientist-executive with over 30 years' experience in biotechnology and entrepreneurial activities. Dr. Payan received his BS and MS in Physics from Stanford and MIT, respectively. He received his MD from Stanford University ..